Amy Jennings

Amy Jennings brings to Locanabio over 20 years of product development experience in the biotechnology and biopharmaceutical industry, 17+ of which have been in regulatory affairs. In her career Amy has contributed to >15 US INDs along with many ex-US CTAs across a number of therapeutic areas and 6 marketing authorization applications (e.g., NDA/BLAs/MAA) along with several supplemental NDAs and variations. Most recently Amy was the Senior Vice President and Head of Regulatory Affairs at Casebia Therapeutics, a joint venture between CRISPR Therapeutics and Bayer focused on gene editing where she developed global development and regulatory strategies for cell and gene editing products to treat autoimmune, ophthalmic and hematologic related diseases. Prior to Casebia, Amy was the Senior Vice President and Head of Regulatory at Achillion Pharmaceuticals, where she was responsible for global regulatory strategy, regulatory operations, quality assurance and medical writing. During her time at Achillion, Amy led successful IND submissions for two rare disease indications. Earlier, Amy served as Sanofi’s associate vice president for global regulatory affairs in the company’s North American diabetes program. Before Sanofi, Amy held positions of increasing responsibility at Bristol-Myers Squibb, including leadership of US regulatory affairs for its cardiovascular/metabolic programs. Amy was a post-doctoral fellow at the Harvard-affiliated Joslin Diabetes Center. She received her Ph.D. in Biochemistry from The Ohio State University and her Bachelor of Science in Chemistry from the University of Wisconsin-Madison.